CXCL12 and cancer: As we have previously shown in a cohort of 183 patients [28], CXCL12 immunoreactivity in cancer cells was heterogeneous, with scores of 0 (undetectable production) obtained in 16 patients and of 5 to 7 (strong immunoreactivity) obtained in eight patients in our cohort of 54 patients.